Alnylam Pharmaceuticals (ALNY) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 95.2% versus a loss of 51.2%. Over five years, TEVA leads with a +304.8% price change compared with +7.6% for ALNY. Teva Pharmaceutical Industries is the larger company by market cap ($45.57 billion vs $29.61 billion), about 1.5 times the size, while Alnylam Pharmaceuticals is growing revenue faster (+65.2% vs +4.3%).
On valuation, Teva Pharmaceutical Industries trades at a lower forward P/E (12.6x vs 17.7x for Alnylam Pharmaceuticals). Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus 8.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | TEVA |
|---|---|---|
| Share price | $221.26 | $39.07 |
| Market cap | $29.61B | $45.57B |
| 1-day change | -1.40% | -0.28% |
| YTD return | -43.57% | +25.54% |
| 1-year return | -51.17% | +95.22% |
| 5-year return | +7.60% | +304.75% |
| P/E ratio (TTM) | 37.31 | 65.12 |
| Forward P/E | 17.74 | 12.64 |
| EPS (TTM) | $5.93 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $17.26B |
| Revenue growth (YoY) | +65.19% | +4.32% |
| Net income (latest FY) | $313.75M | $1.41B |
| Gross margin | 81.77% | 51.79% |
| Operating margin | 13.51% | 12.50% |
| Net margin | 8.45% | 8.17% |
| 52-week high | $495.55 | $40.79 |
| 52-week low | $197.81 | $18.83 |
| Distance from 52-week high | -55.35% | -4.22% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +67.73% | +15.95% |
| Average volume | 1.84M | 5.29M |
| Shares outstanding | 133.81M | 1.17B |
| Employees | 2,500 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TEVA has outperformed ALNY by 146.4 percentage points over the past year.
- Teva Pharmaceutical Industries trades at a higher earnings multiple (65.1x vs 37.3x trailing P/E).
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +4.32%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
ALNY vs TEVA FAQ
Which is bigger, Alnylam Pharmaceuticals or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.57B compared with $29.61B for Alnylam Pharmaceuticals (ALNY).
Which stock has performed better over the past year, ALNY or TEVA?
TEVA returned +95.22% over the past 12 months, compared with -51.17% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or TEVA?
ALNY has the lower trailing P/E at 37.3, versus 65.1 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alnylam Pharmaceuticals and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.